Your shopping cart is currently empty

AVN-101 is a highly potent 5-HT7 receptor antagonist with a Ki value of 153 pM. AVN-101 also exhibits considerable affinity for histamine H1 (Ki value of 0.58 nM) and adrenergic α2A, α2B and α2C (Ki values of 0.41-3.6 nM) receptors. AVN-101 has shown good oral bioavailability and brain-blood barrier permeability, low toxicity and reasonable efficacy in animal models of central nervous system diseases.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $73 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $228 | In Stock | In Stock | |
| 50 mg | $372 | In Stock | In Stock | |
| 100 mg | $619 | In Stock | In Stock | |
| 200 mg | $877 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | AVN-101 is a highly potent 5-HT7 receptor antagonist with a Ki value of 153 pM. AVN-101 also exhibits considerable affinity for histamine H1 (Ki value of 0.58 nM) and adrenergic α2A, α2B and α2C (Ki values of 0.41-3.6 nM) receptors. AVN-101 has shown good oral bioavailability and brain-blood barrier permeability, low toxicity and reasonable efficacy in animal models of central nervous system diseases. |
| Targets&IC50 | α2B-adrenoceptor:0.41 nM (Ki), 5-HT7:153 pM(Ki), 5-HT2C receptor:1.17 nM (Ki), 5-HT1B receptor:720 nM (Ki), 5-HT6 receptor:2.04 nM (Ki), α1D-adrenoceptor:30.2 nM (Ki), 5-HT2B receptor:10.6 nM (Ki), α2A-adrenoceptor:1.77 nM (Ki), 5-HT1A receptor:61 nM (Ki), α2:0.41-3.6 nM(Ki), α2C-adrenoceptor:3.55 nM (Ki), 5-HT2A receptor:1.56 nM (Ki), H1:0.58 nM(Ki), α1B-adrenoceptor:9.4 nM (Ki), α1A-adrenoceptor:18.9 nM (Ki) |
| In vitro | METHODS: The ability of AVN-101 to block hERG channels was tested in single-cell patch clamp experiments using HEK cells stably expressing hERG potassium channels and measuring potassium currents. RESULTS Both AVN-101 and M1 blocked hERG channels with an IC50 score of 0.58 μM. [2] |
| In vivo | METHODS: AVN-101 (5 mg/kg) was evaluated in Wistar rats when administered by oral (PO) and intravenous (I.v) routes. AVN-101 was detected in plasma using LC-MS/MS. RESULTS The bioavailability of AVN-101 in rats (calculated based on AUC0 ⟶240 values) was 26.3% when injected intraperitoneally and 8.5% when administered orally. However, it should be noted that the drug elimination rate determined in the in vivo experiments, Kel = 0.0121 min-1 (i.v.), was significantly slower than that observed in rat microsomes (Kel = 0.335 min-1). [1] |
| Molecular Weight | 340.89 |
| Formula | C21H25ClN2 |
| Cas No. | 1061354-48-0 |
| Smiles | Cl.CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=CC=C1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (176.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.